

Nivolumab CheckMate 066

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Long term plateau in the survival curve



Nivolumab CheckMate 066

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults

Experimental Arm: Nivolumab

Control Arm: Dacarbazine



